Glucocorticoids are potent inhibitors of T cell activation and proinflammatory cytokines and are highly effective treatment for active inflammatory bowel disease (IBD). However, failure to respond, acutely or chronically, to glucocorticoid therapy is a common indication for surgery in IBD, with as many as 50% of patients with Crohn's disease (CD) and approximately 20% of patients with ulcerative colitis (UC) requiring surgery in their lifetime as a result of poor response to glucocorticoids. Studies report that approximately one-third of patients with CD are steroid dependent and one-fifth are steroid resistant while approximately one-quarter of patients with UC are steroid dependent and one-sixth are steroid resistant. While the molecular basis of glucocorticoid resistance has been widely assessed in other inflammatory conditions, the pathophysiology of the glucocorticoid resistance in IBD is poorly understood. Research in IBD suggests that the phenomenon of glucocorticoid resistance is compartmentalised to T-lymphocytes and possibly other target inflammatory cells. This review focuses on three key molecular mechanisms of glucocorticoid resistance in IBD: (i) decreased cytoplasmic glucocorticoid concentration secondary to increased P-glycoprotein-mediated efflux of glucocorticoid from target cells due to overexpression of the multidrug resistance gene (MDR1); (ii) impaired glucocorticoid signaling because of dysfunction at the level of the glucocorticoid receptor; and (iii) constitutive epithelial activation of proinflammatory mediators, including nuclear factor kappa B, resulting in inhibition of glucocorticoid receptor transcriptional activity. In addition, the impact of disease heterogeneity on glucocorticoid responsiveness and recent advances in IBD pharmacogenetics are discussed.

This article has been cited by other articles:

				G. U. Meduri, D. Annane, G. P. Chrousos, P. E. Marik, and S. E. Sinclair Activation and Regulation of Systemic Inflammation in ARDS: Rationale for Prolonged Glucocorticoid Therapy Chest, December 1, 2009; 136(6): 1631 - 1643. [Abstract] [Full Text] [PDF]

				T. J. Creed, R. W. Lee, P. V. Newcomb, A. J. di Mambro, M. Raju, and C. M. Dayan The Effects of Cytokines on Suppression of Lymphocyte Proliferation by Dexamethasone J. Immunol., July 1, 2009; 183(1): 164 - 171. [Abstract] [Full Text] [PDF]

				M. K Vihinen, K.-L. Kolho, M. Ashorn, M. Verkasalo, and T. Raivio Bone turnover and metabolism in paediatric patients with inflammatory bowel disease treated with systemic glucocorticoids Eur. J. Endocrinol., December 1, 2008; 159(6): 693 - 698. [Abstract] [Full Text] [PDF]

				A. G. Atanasov, D. Leiser, C. Roesselet, M. Noti, N. Corazza, K. Schoonjans, and T. Brunner Cell cycle-dependent regulation of extra-adrenal glucocorticoid synthesis in murine intestinal epithelial cells FASEB J, December 1, 2008; 22(12): 4117 - 4125. [Abstract] [Full Text] [PDF]

				S Tsujimura, K Saito, M Nawata, S Nakayamada, and Y Tanaka Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis Ann Rheum Dis, March 1, 2008; 67(3): 380 - 388. [Abstract] [Full Text] [PDF]

				S. Cuzzocrea, S. Bruscoli, E. Mazzon, C. Crisafulli, V. Donato, R. Di Paola, E. Velardi, E. Esposito, G. Nocentini, and C. Riccardi Peroxisome Proliferator-Activated Receptor-{alpha} Contributes to the Anti-Inflammatory Activity of Glucocorticoids Mol. Pharmacol., February 1, 2008; 73(2): 323 - 337. [Abstract] [Full Text] [PDF]

				R. Oerlemans, J. Vink, B. A C Dijkmans, Y. G Assaraf, M. van Miltenburg, J. van der Heijden, I. Ifergan, W. F Lems, R. J Scheper, G. J L Kaspers, et al. Sulfasalazine sensitises human monocytic/macrophage cells for glucocorticoids by upregulation of glucocorticoid receptor {alpha} and glucocorticoid induced apoptosis Ann Rheum Dis, October 1, 2007; 66(10): 1289 - 1295. [Abstract] [Full Text] [PDF]

				S. De Iudicibus, G. Stocco, S. Martelossi, I. Drigo, S. Norbedo, P. Lionetti, E. Pozzi, A. Barabino, G. Decorti, F. Bartoli, et al. Association of BclI polymorphism of the glucocorticoid receptor gene locus with response to glucocorticoids in inflammatory bowel disease Gut, September 1, 2007; 56(9): 1319 - 1320. [Full Text] [PDF]

				S. Tsujimura, K. Saito, K. Kohno, and Y. Tanaka Fragmented Hyaluronan Induces Transcriptional Up-regulation of the Multidrug Resistance-1 Gene in CD4+ T Cells J. Biol. Chem., December 8, 2006; 281(49): 38089 - 38097. [Abstract] [Full Text] [PDF]

				F. N. C. Gropp, D. L. Greger, C. Morel, S. Sauter, and J. W. Blum Nuclear receptor and nuclear receptor target gene messenger ribonucleic acid levels at different sites of the gastrointestinal tract and in liver of healthy dogs J Anim Sci, October 1, 2006; 84(10): 2684 - 2691. [Abstract] [Full Text] [PDF]

				O. Tliba, J. A. Cidlowski, and Y. Amrani CD38 Expression Is Insensitive to Steroid Action in Cells Treated with Tumor Necrosis Factor-{alpha} and Interferon-{gamma} by a Mechanism Involving the Up-Regulation of the Glucocorticoid Receptor beta Isoform Mol. Pharmacol., February 1, 2006; 69(2): 588 - 596. [Abstract] [Full Text] [PDF]

				A. Lamprecht, H. Yamamoto, H. Takeuchi, and Y. Kawashima Nanoparticles Enhance Therapeutic Efficiency by Selectively Increased Local Drug Dose in Experimental Colitis in Rats J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 196 - 202. [Abstract] [Full Text] [PDF]

				S. Resta-Lenert, J. Smitham, and K. E. Barrett Epithelial dysfunction associated with the development of colitis in conventionally housed mdr1a-/- mice Am J Physiol Gastrointest Liver Physiol, July 1, 2005; 289(1): G153 - G162. [Abstract] [Full Text] [PDF]

				N.C. Thomson, R. Chaudhuri, and E. Livingston Asthma and cigarette smoking Eur. Respir. J., November 1, 2004; 24(5): 822 - 833. [Abstract] [Full Text] [PDF]

				Z. Szatmary, M. J. Garabedian, and J. Vilcek Inhibition of Glucocorticoid Receptor-mediated Transcriptional Activation by p38 Mitogen-activated Protein (MAP) Kinase J. Biol. Chem., October 15, 2004; 279(42): 43708 - 43715. [Abstract] [Full Text] [PDF]